BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 20850937)

  • 21. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
    Hussein MR; Abd-Elwahed SR; Abdulwahed AR
    Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
    Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
    Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas.
    Wei B; Wang J; Bourne P; Yang Q; Hicks D; Bu H; Tang P
    Hum Pathol; 2008 Dec; 39(12):1809-15. PubMed ID: 18715613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma--relation with grade, stage, estrogen receptor and HER2.
    Kusińska R; Potemski P; Jesionek-Kupnicka D; Kordek R
    Pol J Pathol; 2005; 56(3):107-10. PubMed ID: 16334976
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes.
    Kos T; Aksoy S; Sendur MA; Arik Z; Civelek B; Kandemir N; Ozdemir NY; Zengin N; Altundag K
    J BUON; 2013; 18(3):608-13. PubMed ID: 24065471
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinicopathologic features and five years survival analysis in molecular subtypes of breast cancer.
    Zaha DC; Lazăr E; Lăzureanu C
    Rom J Morphol Embryol; 2010; 51(1):85-9. PubMed ID: 20191125
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy.
    Goldstein NS; Decker D; Severson D; Schell S; Vicini F; Margolis J; Dekhne NS
    Cancer; 2007 Oct; 110(8):1687-96. PubMed ID: 17722109
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel.
    Millar EK; Graham PH; O'Toole SA; McNeil CM; Browne L; Morey AL; Eggleton S; Beretov J; Theocharous C; Capp A; Nasser E; Kearsley JH; Delaney G; Papadatos G; Fox C; Sutherland RL
    J Clin Oncol; 2009 Oct; 27(28):4701-8. PubMed ID: 19720911
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
    Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
    J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.
    Bartlett JM; Ellis IO; Dowsett M; Mallon EA; Cameron DA; Johnston S; Hall E; A'Hern R; Peckitt C; Bliss JM; Johnson L; Barrett-Lee P; Ellis P
    J Clin Oncol; 2007 Oct; 25(28):4423-30. PubMed ID: 17906205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The relevance of intrinsic subtype to clinicopathological features and prognosis in 4,266 Japanese women with breast cancer.
    Shibuta K; Ueo H; Furusawa H; Komaki K; Rai Y; Sagara Y; Kamada Y; Tamaki N
    Breast Cancer; 2011 Oct; 18(4):292-8. PubMed ID: 20571962
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of HER-2 over-expression with clinico-pathological parameters in Tunisian breast carcinoma.
    Ayadi L; Khabir A; Amouri H; Karray S; Dammak A; Guermazi M; Boudawara T
    World J Surg Oncol; 2008 Oct; 6():112. PubMed ID: 18945339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma.
    González LO; Corte MD; Junquera S; González-Fernández R; del Casar JM; García C; Andicoechea A; Vázquez J; Pérez-Fernández R; Vizoso FJ
    Hum Pathol; 2009 Sep; 40(9):1224-33. PubMed ID: 19439346
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Primary breast cancer phenotypes associated with propensity for central nervous system metastases.
    Tham YL; Sexton K; Kramer R; Hilsenbeck S; Elledge R
    Cancer; 2006 Aug; 107(4):696-704. PubMed ID: 16826579
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.
    Ariga R; Zarif A; Korasick J; Reddy V; Siziopikou K; Gattuso P
    Breast J; 2005; 11(4):278-80. PubMed ID: 15982396
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The hormone receptor, human epidermal growth factor receptor 2, and molecular subtype status of individual tumor foci in multifocal/multicentric invasive ductal carcinoma of breast.
    Choi Y; Kim EJ; Seol H; Lee HE; Jang MJ; Kim SM; Kim JH; Kim SW; Choe G; Park SY
    Hum Pathol; 2012 Jan; 43(1):48-55. PubMed ID: 21733550
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
    Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
    Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of a basal-like subtype of breast ductal carcinoma in situ.
    Livasy CA; Perou CM; Karaca G; Cowan DW; Maia D; Jackson S; Tse CK; Nyante S; Millikan RC
    Hum Pathol; 2007 Feb; 38(2):197-204. PubMed ID: 17234468
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Triple-negative breast carcinoma in women from Vietnam and the United States: characterization of differential marker expression by tissue microarray.
    Williams DJ; Cohen C; To TV; Page AJ; Lawson D; Sussman ZM; Nassar A
    Hum Pathol; 2009 Aug; 40(8):1176-81. PubMed ID: 19368951
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.